NewcelX Ltd. (NCEL)
NCEL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | NCEL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | 2021 |
| SEC CIK | 0001783036 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Switzerland |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements." | 20-F 2026-04-29 |
| Cash and burn | $2.2M cash; operating cash flow -$692K a quarter. | Report 2025-12-31 |
| Shares outstanding | 4,797,505 (2025-12-31); 3,159,535 a year earlier; 32,428,893 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-400 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2025-10-31 | Source 2025-10-31 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-08-20 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE/A filed | 25-NSE/A 2025-10-30 |
| Auditor | Kost Forer Gabbay & Kasierer, Tel Aviv, Israel | PCAOB Form AP 2026-05-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $375K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$8.3M | -$2.8M | $2.2M | $355K | Needs four quarters | 20-F 2026-04-29 |
| FY 2024 2024-12-31 | Not filed | -$7.2M | -$1.1M | $650K | $7.7M | Needs four quarters | 20-F 2026-04-29 |
| FY 2023 2023-12-31 | Not filed | -$3.3M | -$3.4M | $1.1M | No debt tags | Needs four quarters | 20-F 2026-04-29 |
| FY 2022 2022-12-31 | Not filed | -$16.5M | -$13.9M | $8.9M | No debt tags | Needs four quarters | 20-F 2025-05-16 |
| FY 2021 2021-12-31 | Not filed | -$11.9M | -$14.9M | $5.4M | No debt tags | Needs four quarters | 20-F 2024-05-15 |
| FY 2020 2020-12-31 | Not filed | -$2.9M | -$729K | $94K | $113K | Needs four quarters | 20-F 2023-05-05 |
| FY 2019 2019-12-31 | Not filed | -$5.4M | -$190K | $220K | $692K | Needs four quarters | 20-F 2022-03-24 |
| FY 2018 2018-12-31 | Not filed | -$5.1M | -$2.7M | $7K | No debt tags | Needs four quarters | 20-F 2021-05-14 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 | POS AM | 2026-09-18 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-04-29 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-09 |
Source: SEC EDGAR submissions feed, 419 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.2% |
| 1 month | -8.1% |
| 3 months | -27.5% |
| Year to date | +37.4% |
| 1 year | -23.9% |
| From 52-week high | -46.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CNTX | Context Therapeutics Inc. | $0.1659 | -8.24% | $15.2M |
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
| KTTA | Pasithea Therapeutics Corp. | $0.5000 | -4.21% | $16.7M |
| PBM | Psyence Biomedical Ltd. Common Shares | $2.83 | -11.56% | $15.0M |
| QNRX | Quoin Pharmaceuticals Ltd. | $3.56 | -3.78% | $17.1M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier